R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD)

Sharon Moe, Mark F. Seifert, Xuening (Neal) Chen, Rachel M. Sinders, Xianming Chen, Dana Duan, Charles Henley, Dave Martin, Vincent H. Gattone

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background. Chronic kidney disease-mineral bone disorder (CKD-MBD), a newly defined disorder in patients with CKD, describes the interacting triad of (1) biochemical abnormalities of calcium, phosphorus and parathyroid hormone (PTH), (2) extraskeletal calcification and (3) abnormal bone.Methods. We studied the effects of the calcimimetic R-568, R-568 with calcium (R-568 + Ca) or calcium (Ca) alone compared with control CKD rats on this triad in the Cy+ male rat, a model of progressive CKD that spontaneously develops CKD-MBD on a normal phosphorus diet. Animals were treated for either 14 or 18 weeks beginning at 20 weeks of age (34-week and 38-week animals, respectively).Results. The results demonstrated similar efficacy of R-568, R-568 + Ca and Ca in lowering PTH levels. R-568 alone lowered plasma calcium compared to control over time, but increased phosphorus compared to control early in the course of the disease, but not at 38 weeks. Animals treated with Ca alone or R-568 + Ca had lower phosphorus levels; the Ca alone group had elevated Ca levels. Bone volume improved in the calcium-treated groups. In contrast, arterial and cardiac calcification worsened by most assessments in the R-568 + Ca and Ca alone treated animals compared with R-568 alone whereas R-568 alone treatment showed beneficial effects on most sites of extraskeletal calcification.Conclusion. Thus, R-568, with or without Ca, improved the biochemical abnormalities of hyperparathyroidism but with higher and lower calcium levels, respectively, compared with controls. However, R-568 + Ca had more dramatic improvement in bone volume, but more extraskeletal calcification than R-568 alone. This complexity demonstrates that treatment of one component of CKD-MBD may lead to undesirable effects on other components.

Original languageEnglish
Pages (from-to)2371-2377
Number of pages7
JournalNephrology Dialysis Transplantation
Volume24
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine
Chronic Kidney Disease-Mineral and Bone Disorder
Calcium
Phosphorus
Parathyroid Hormone
Bone and Bones

Keywords

  • Kidney
  • Mineral bone disorder
  • Parathyroid hormone
  • Renal osteodystrophy
  • Vascular calcification

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). / Moe, Sharon; Seifert, Mark F.; Chen, Xuening (Neal); Sinders, Rachel M.; Chen, Xianming; Duan, Dana; Henley, Charles; Martin, Dave; Gattone, Vincent H.

In: Nephrology Dialysis Transplantation, Vol. 24, No. 8, 08.2009, p. 2371-2377.

Research output: Contribution to journalArticle

Moe, Sharon ; Seifert, Mark F. ; Chen, Xuening (Neal) ; Sinders, Rachel M. ; Chen, Xianming ; Duan, Dana ; Henley, Charles ; Martin, Dave ; Gattone, Vincent H. / R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). In: Nephrology Dialysis Transplantation. 2009 ; Vol. 24, No. 8. pp. 2371-2377.
@article{22bb7db014e74772a2fce1d3dbca8a0c,
title = "R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD)",
abstract = "Background. Chronic kidney disease-mineral bone disorder (CKD-MBD), a newly defined disorder in patients with CKD, describes the interacting triad of (1) biochemical abnormalities of calcium, phosphorus and parathyroid hormone (PTH), (2) extraskeletal calcification and (3) abnormal bone.Methods. We studied the effects of the calcimimetic R-568, R-568 with calcium (R-568 + Ca) or calcium (Ca) alone compared with control CKD rats on this triad in the Cy+ male rat, a model of progressive CKD that spontaneously develops CKD-MBD on a normal phosphorus diet. Animals were treated for either 14 or 18 weeks beginning at 20 weeks of age (34-week and 38-week animals, respectively).Results. The results demonstrated similar efficacy of R-568, R-568 + Ca and Ca in lowering PTH levels. R-568 alone lowered plasma calcium compared to control over time, but increased phosphorus compared to control early in the course of the disease, but not at 38 weeks. Animals treated with Ca alone or R-568 + Ca had lower phosphorus levels; the Ca alone group had elevated Ca levels. Bone volume improved in the calcium-treated groups. In contrast, arterial and cardiac calcification worsened by most assessments in the R-568 + Ca and Ca alone treated animals compared with R-568 alone whereas R-568 alone treatment showed beneficial effects on most sites of extraskeletal calcification.Conclusion. Thus, R-568, with or without Ca, improved the biochemical abnormalities of hyperparathyroidism but with higher and lower calcium levels, respectively, compared with controls. However, R-568 + Ca had more dramatic improvement in bone volume, but more extraskeletal calcification than R-568 alone. This complexity demonstrates that treatment of one component of CKD-MBD may lead to undesirable effects on other components.",
keywords = "Kidney, Mineral bone disorder, Parathyroid hormone, Renal osteodystrophy, Vascular calcification",
author = "Sharon Moe and Seifert, {Mark F.} and Chen, {Xuening (Neal)} and Sinders, {Rachel M.} and Xianming Chen and Dana Duan and Charles Henley and Dave Martin and Gattone, {Vincent H.}",
year = "2009",
month = "8",
doi = "10.1093/ndt/gfp078",
language = "English",
volume = "24",
pages = "2371--2377",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD)

AU - Moe, Sharon

AU - Seifert, Mark F.

AU - Chen, Xuening (Neal)

AU - Sinders, Rachel M.

AU - Chen, Xianming

AU - Duan, Dana

AU - Henley, Charles

AU - Martin, Dave

AU - Gattone, Vincent H.

PY - 2009/8

Y1 - 2009/8

N2 - Background. Chronic kidney disease-mineral bone disorder (CKD-MBD), a newly defined disorder in patients with CKD, describes the interacting triad of (1) biochemical abnormalities of calcium, phosphorus and parathyroid hormone (PTH), (2) extraskeletal calcification and (3) abnormal bone.Methods. We studied the effects of the calcimimetic R-568, R-568 with calcium (R-568 + Ca) or calcium (Ca) alone compared with control CKD rats on this triad in the Cy+ male rat, a model of progressive CKD that spontaneously develops CKD-MBD on a normal phosphorus diet. Animals were treated for either 14 or 18 weeks beginning at 20 weeks of age (34-week and 38-week animals, respectively).Results. The results demonstrated similar efficacy of R-568, R-568 + Ca and Ca in lowering PTH levels. R-568 alone lowered plasma calcium compared to control over time, but increased phosphorus compared to control early in the course of the disease, but not at 38 weeks. Animals treated with Ca alone or R-568 + Ca had lower phosphorus levels; the Ca alone group had elevated Ca levels. Bone volume improved in the calcium-treated groups. In contrast, arterial and cardiac calcification worsened by most assessments in the R-568 + Ca and Ca alone treated animals compared with R-568 alone whereas R-568 alone treatment showed beneficial effects on most sites of extraskeletal calcification.Conclusion. Thus, R-568, with or without Ca, improved the biochemical abnormalities of hyperparathyroidism but with higher and lower calcium levels, respectively, compared with controls. However, R-568 + Ca had more dramatic improvement in bone volume, but more extraskeletal calcification than R-568 alone. This complexity demonstrates that treatment of one component of CKD-MBD may lead to undesirable effects on other components.

AB - Background. Chronic kidney disease-mineral bone disorder (CKD-MBD), a newly defined disorder in patients with CKD, describes the interacting triad of (1) biochemical abnormalities of calcium, phosphorus and parathyroid hormone (PTH), (2) extraskeletal calcification and (3) abnormal bone.Methods. We studied the effects of the calcimimetic R-568, R-568 with calcium (R-568 + Ca) or calcium (Ca) alone compared with control CKD rats on this triad in the Cy+ male rat, a model of progressive CKD that spontaneously develops CKD-MBD on a normal phosphorus diet. Animals were treated for either 14 or 18 weeks beginning at 20 weeks of age (34-week and 38-week animals, respectively).Results. The results demonstrated similar efficacy of R-568, R-568 + Ca and Ca in lowering PTH levels. R-568 alone lowered plasma calcium compared to control over time, but increased phosphorus compared to control early in the course of the disease, but not at 38 weeks. Animals treated with Ca alone or R-568 + Ca had lower phosphorus levels; the Ca alone group had elevated Ca levels. Bone volume improved in the calcium-treated groups. In contrast, arterial and cardiac calcification worsened by most assessments in the R-568 + Ca and Ca alone treated animals compared with R-568 alone whereas R-568 alone treatment showed beneficial effects on most sites of extraskeletal calcification.Conclusion. Thus, R-568, with or without Ca, improved the biochemical abnormalities of hyperparathyroidism but with higher and lower calcium levels, respectively, compared with controls. However, R-568 + Ca had more dramatic improvement in bone volume, but more extraskeletal calcification than R-568 alone. This complexity demonstrates that treatment of one component of CKD-MBD may lead to undesirable effects on other components.

KW - Kidney

KW - Mineral bone disorder

KW - Parathyroid hormone

KW - Renal osteodystrophy

KW - Vascular calcification

UR - http://www.scopus.com/inward/record.url?scp=67649732072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649732072&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfp078

DO - 10.1093/ndt/gfp078

M3 - Article

VL - 24

SP - 2371

EP - 2377

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 8

ER -